MET and non-small cell lung carcinoma: Several studies are underway evaluating role of ALK inhibitors like X-396 (Xcovery Holding Company, West Palm Beach, FL, USA), MET/HGF TKIs like PF-02341066 (Pfizer, Groton, CT, USA), and onartuzumab/MetMAb (Genentech Inc., South San Francisco, CA, USA) in NSCLC (Table 1).